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Available online 6 May 2006Seladin-1 (SELective Alzheimer's Disease INdicator-1) is an anti-apoptotic gene, which is
down-regulated in brain regions affected by Alzheimer's disease (AD). In addition, seladin-1
catalyzes the conversion of desmosterol into cholesterol. Disruption of cholesterol
homeostasis in neurons may increase cell susceptibility to toxic agents. Because the
hippocampus and the subventricular zone, which are affected in AD, are the unique regions
containing stem cells with neurogenic potential in the adult brain, it might be hypothesized
that this multipotent cell compartment is the predominant source of seladin-1 in normal
brain. In the present study, we isolated and characterized human mesenchymal stem cells
(hMSC) as a model of cells with the ability to differentiate into neurons. hMSC were then
differentiated toward a neuronal phenotype (hMSC-n). These cells were thoroughly
characterized and proved to be neurons, as assessed by molecular and electrophysiological
evaluation. Seladin-1 expression was determined and found to be significantly reduced in
hMSC-n compared to undifferentiated cells. Accordingly, the total content of cholesterol was
decreased after differentiation. These original results demonstrate for the first time that
seladin-1 is abundantly expressed by stem cells and appear to suggest that reduced
expression in AD might be due to an altered pool of multipotent cells.
© 2006 Elsevier Inc. All rights reserved.Keywords:
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A few years ago, a novel gene, named seladin-1 (for
SELective Alzheimer's Disease INdicator-1), was identified
and associated to neurodegeneration. In fact, this gene was
found to be down-regulated in brain regions affected by
Alzheimer's disease (AD) [1]. Conversely, overexpression of
seladin-1 conferred protection against β-amyloid-mediated
toxicity and from oxidative stress in neuroglioma H4 cells.
In addition, seladin-1 effectively inhibited caspase 3 activ-
ity, a key mediator of apoptosis, and protected from
apoptotic death [1]. Accordingly, we have recently demon-
strated in long-term cell cultures from human fetal
olfactory epithelium that seladin-1, which is up-regulated
by estrogen and Selective Estrogen Receptor Modulators,
confers resistance to both β-amyloid-induced toxicity and
oxidative stress [2]. Following its first description, a
subsequent study demonstrated that seladin-1 possesses
also enzymatic activity because its gene sequence was
found to be identical to that of the gene encoding 3-beta-
hydroxysterol delta-24-reductase (DHCR24) [3], which con-
verts desmosterol into cholesterol. Disruption of cholesterol
homeostasis may be detrimental for cells because a
cholesterol-depleted membrane would ease the interaction
with toxic factors such as β-amyloid [4]. With regard to its
enzymatic activity, seladin-1 has been regarded as the
human homologue of the Diminuto/Dwarf1 gene, which is
required in plants for the synthesis of brassinosteroids, a
class of sterols essential for normal growth and develop-
ment [5,6]. In humans, mutations of the seladin-1 gene have
been found in desmosterolosis, a rare severe multiple-
congenital-anomaly syndrome, including developmental
and growth retardation [3].
The hippocampus and the subventricular zone are two of
the brain areas affected in AD [7]. Interestingly, these are the
unique regions in which stem cells with a defined neuro-
genic potential are located in the adult brain [8]. In fact,
although neural stem cells are present in many other areas
of the adult brain, they do not appear to maintain the ability
to differentiate into neurons [8]. Very recently, stem cells
with neurogenic activity have been described also in the
adult spinal cord [9,10], which classically was not considered
a neurogenic region [11]. Noteworthy, Greeve et al. [1]
detected the presence of rather high levels of expression of
seladin-1 both in human normal hippocampus and spinal
cord [1]. We hypothesized that, if seladin-1 expression is
reduced in AD, stem cells might be the prevalent source of
this protein. In order to test this hypothesis, we used
mesenchymal stem cells (MSC), which have been reported
to differentiate into different cell types in addition to
mesenchymal derivatives, including neurons [12–15]. Admit-
tedly, in our experimental design, this cell model might
represent a reasonable alternative to the use of neuronal
stem cells, which are much more difficult to obtain. In our
hands, human MSC, obtained from aspirates taken from the
iliac crest of normal young volunteers, were subjected to
neuronal differentiation and both seladin-1 expression and
the content of total cholesterol were determined in both
undifferentiated and differentiated cells.Materials and methods
Materials
Media and sera for cell cultures were purchased from
Euroclone (Wetherby, West York, UK), and tissue plastic-
ware was obtained from GreinerBio-One (Frickenhausen,
Germany). Neurobasal medium was obtained from Life
Technologies (Invitrogen, S. Giuliano Milanese, Milan, Italy).
Other reagents for cell cultures were obtained from Sigma
(Milan, Italy). Ultroser-G (UG) was purchased from Pall
BioSepra SA (Cergy Saint Christophe, France). Flow cytometry
buffer (CellWASH) was from Becton Dickinson (Franklin Lakes,
NJ). Monoclonal antibodies for flow cytometry immunophe-
notyping were obtained from BD Pharmingen (San Diego, CA)
and Ancell (St.N. Bayport, MN), whereas antibodies for
immunocytochemistry were from Chemicon (Temecula, CA).
For RNA extraction, the Nucleospin®RNAII kit was purchased
from Macherey-Nagel (Duren, Germany). Reagents for RT-PCR
studies were from Applied Biosystem Inc. (Foster City, CA).
Cholesterol, Bradford reagent and N,O-bis(trimethylsilyl)-tri-
fluoroacetamide (BSTFA) were from Sigma. Stigmasterol was
from Steraloids Inc. (Newport, RI, USA). Pooled total RNAs
from human adult tissues were from Clontech (Mountain
View, CA).
Isolation, culture and characterization of human
mesenchymal stem cells (hMSC)
Human bone marrow cells were obtained from the iliac crest
of normal donors marrow aspirates. Informed consent was
obtained from all donors, and the institutional ethical
committee approved all the procedures. Whole bone marrow
was collected, and small aliquots were centrifuged for 10 min
at 700×g; the white blood cells buffy coat was recovered and
plated in 75 cm 2 flasks (1.6 × 105 cells/cm2) in Iscove's MDM
(with L-glutamine and 25 mM HEPES) with 50 μg/ml gentamy-
cin, 10% FBS and 2% UG. Cells were then incubated at 37°C in
fully humidified atmosphere containing 95% air and 5% CO2.
On reaching confluence, the adherent cells were detached by
0.05% trypsin and 0.02% EDTA for 5–10 min at 37°C, harvested
and washed with HBSS and 10% FBS and finally resuspended
in complete medium (primary culture, P0). Cells were re-
seeded at 104 cells/cm2 in 100-mm dishes (P1) for both in vitro
differentiation assessment and further cellular expansion
which was achieved by successive cycles of trypsinization
and re-seeding.
The frequency of Colony Forming Units-Fibroblasts (CFU-F)
was measured using the method of Castro-Malaspina [16].
Visible colonies with 50 or more cells (the conventional value
for defining a colony) [17] were counted and referred to 106
plated cells (no. of CFU-F/106 TNC).
Immunophenotyping and differentiation of hMSC
At the first passage, the morphologically homogeneous
population of hMSC was analyzed for the expression of cell
surface molecules using flow cytometry procedures: hMSC,
recovered from flasks by trypsin–EDTA treatment and washed
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(0.1% sodium azide in PBS) with 2% FBS. Aliquots (1.5 × 105
cells/100 μl) were incubated with the following conjugated
monoclonal antibodies: CD34-PE, CD45-FITC, CD14-PE (in
order to quantify hemopoietic–monocytic contamination);
CD29-PE, CD44-FITC, CD166-PE, CD90-PE, CD73-PE, HLA-DP
QR-FITC, HLA-ABC-FITC (BD Pharmingen, San Diego, CA) and
CD105-PE (Ancell, St.N. Bayport, MN). Non-specific fluores-
cence and morphologic parameters of the cells were deter-
mined by incubation of the same cell aliquot with isotype-
matched mouse monoclonal antibodies. Incubations were
performed for 20 min, and thereafter the cells were washed
and resuspended in 100 μl of CellWASH; 7-AAD was added in
order to exclude dead cells from the analysis. Flow cytometric
acquisition was performed by collecting 104 events on a
FACScan (argon laser equipped; Becton Dickinson) instru-
ment, and data were analyzed on DOT-PLOT bi-parametric
diagrams using CELL QUEST software (Becton Dickinson,
Franklin Lakes, NJ, USA) on Macintosh PC.
The ability of MSC to differentiate along osteogenic,
adipogenic and chondrogenic lineages was assayed, as
described previously by Pittenger et al. [18]. Osteogenic,
chondrogenic and adipogenic differentiation were evaluated
by cytochemical analysis. Petri dishes were stained to assess
glucosamynoglycans by Toluidine Blue and for extracellular
matrix mineral bound by Alizarin Red-S. Adipogenic differ-
entiation was evaluated by Sudan Black B stain; lipid
droplets were photographed under light microscopy.
Induction of neuronal phenotype
Primary cultures of hMSC were chemically induced towards a
neuronal phenotype (hMSC-n) according to the method of
Woodbury et al. [12] with some modifications. Briefly,
subconfluent cultures in 100 mm dishes were preinduced for
24 h in Neurobasalmedium containing 1mM β-mercaptoetha-
nol (BME) and 10 ng/ml bFGF. The preinduction medium was
then removed, and the cells were washed once with phos-
phate buffered saline (PBS). Successively, hMSC were shifted
into Neurobasal medium containing 10% FCS, 10 mM BME for
further 24 h.
Viability assay
Viable cells were determined in hMSC-n vs. control cells by
Trypan blue dye exclusion test. Briefly, cells were cultured
in 100 mm and were stained with Trypan blue dye for
1 min. Blue-positive and white-negative cells were counted
in ten 20× fields, and the results were expressed as
mean ± SE of viable and dead cells/field in three different
experiments.
RT-PCR studies
Total RNA was isolated using Nucleospin®RNAII (Macherey-
Nagel Duren, Germany) with DNAse treatment according to
the manufacturer's instructions and the concentration
determined spectrophotometrically with Nanodrop® ND-
1000. First strand cDNA was synthesized using “TaqMan
Reverse transcription Reagents” (Applied Biosystem Inc.,Foster city, CA) with Reaction Buffer 1×; MgCl2 5.5 mM;
dNTP's 2 mM; RNAse Inhibitor 1U; random hexamers
1.25 μM; MuLV 2U. In order to identify the presence of
neuronal, osteogenic, chondrogenic and adipogenic markers,
PCR was performed in 25 μl total volume using Mastermix
AmpliTaq Gold (Applied Biosystem Inc., Foster city, CA) 1×,
MgCl2 2 mM, forward and reverse primers 0.4 pmol/μl.
Eppendorf Mastercycler Gradient (Eppendorf Amburg, Ger-
many) was programmed as follows: 1 cycle at 95°C for 120 s,
30 cycles at 95°C for 45 s, 60°C for 45 s, and 45 s at 72°C. The
primers (MWG biotech Germany) are reported in the table.
The PCR products were analyzed on 2% or 3% agarose gels
with ethidium bromide and visualized under UV light by
Kodak Image Station 140 CF.Gene product Genbank accession
numberReferenceOsteocalcin BC033656 [19]
Bone sialoprotein NM004967 [19]
Alkaline phosphatase BC021289 [20]
PPARγ BC006811 [21]
Type I collagen alpha
2 subunitBC042586 [20]Nestin X65964 [22]
Necdin AB007828 [22]
Neurofilament subunit
L (NF-L)X05608 [22]Neurite
outgrowth-promoting
protein (NOPP)X55110 [22]Glypican 4 (GP4) AF030186 [22]
Glial fibrillary acid
protein (GFAP)S40719 [22]Immunocytochemistry
hMSC were cultured into four-chamber slides and induced to
neuronal differentiation as described above. Successively, the
cells were washed twice with PBS and fixed in 4% parafor-
maldehyde and 0.1% glutaraldehyde. hMSC were immunos-
tained for nestin (mouse anti-nestin human antibody), choline
acetyltransferase (ChAT, rabbit anti-choline acetyltransferase
antibody), neuronal nuclei (NeuN,mouse anti-neuronal nuclei
antibody), neurofilament M (NF-M, rabbit anti-neurofilament
M C-terminal antibody). The cells were incubated with
primary antibodies overnight at 4°C, incubated with second-
ary antibodies for 1 h followed by exposure to Vectastain ABC
and AEC reagents (Vector Laboratories, Inc, Burlingame, CA,
USA).
Electrophysiological studies
The electrophysiological behavior of hMSC and hMSC-n was
analyzed by the whole-cell patch-clamp technique in voltage-
clamp conditions. The cells were superfused at a rate of 1.8 ml
min−1 with a control bath solution containing 150 mM NaCl,
5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 10 mM D-glucose and
10mMHEPES. To block K+ channels [23], we used a 20mM-TEA
bath solution containing 122.5 mM NaCl, 2 mM CaCl2, 20 TEA-
OH and 10 mM HEPES. To record Ca2+ currents, a TEA–Ca2+
bath solution (10 mM CaCl2, 145 TEABr and 10 mMHEPES) was
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used to block respectively L-type Ca2+ channels and high
voltage activated (HVA) but T-type Ca2+ channels. The patch
pipettes filling solution contained 150 mM CsBr, 5 mM MgCl2,
10 mM EGTA and 10 mM HEPES. pH was titrated to 7.4 with
NaOH and to 7.2 with TEA-OH for bath and pipette solution,
respectively. Patch electrodes were pulled using a micropi-
pette vertical puller (Narishige PC-10) from borosilicate glass
(GC 150-15; Clark). When filled, the resistance of the pipettes
measured 2–3 MΩ. The patch pipette was connected to a
micromanipulator (Narishige International USA) and an
Axopatch 200B amplifier (Axon Instruments). Voltage-clamp
protocol generation, data acquisition and analysis of data
were as in Francini et al. [24]. Electrode capacitance was
compensated before disrupting the patch. All the passive
properties parameters were estimated as in Formigli et al. [25].
All experiments were performed at room temperature
(20–23°C). The steady-state ionic current activation was
evaluated by
IaðVÞ ¼ GmaxðV  VrevÞ=f1þ exp½Va  V=kag ð1Þ
and steady-state inactivation by
IhðVÞ ¼ If1þ exp½ðVh  VÞ=k hg ð2Þ
where Gmax is the maximal conductance for the Ia, Vrev
is the apparent reversal potential, Va and Vh are the
potentials that elicit the half-maximal size, ka and kh
are the steepness factors.
Quantitative real-time RT-PCR for human Telomerase Reverse
Transcriptase (hTERT) and seladin-1 transcripts
The absolute quantification of hTERT mRNA (in hMSC and
hMSC-n) and seladin-1 mRNA (in hMSC, hMSC exposed to
1 mM BME, 20 and 100 μM H2O2, 50 μM ascorbic acid, hMSC-n,
hMSC-derived osteoblasts, human hippocampus, spinal cord,
adrenal cortex, thyroid) was performed by real-time RT-PCR,
based on TaqMan technologies, as described previously
[26,27]. Because normalization to rRNA or to glyceraldehyde-
3-phosphate-dehydrogenase, as well as to other “housekeep-
ing” genes, has been clearly shown to be not accurate [28], the
results were referred to microgram of total RNA. The experi-
ments (n = 3) were run in triplicates.
Western blot analysis for seladin-1
The amount of seladin-1 protein in hMSC and in hMSC-n was
determined by Western blot analysis, as described previously
[27] using a rabbit polyclonal anti-seladin-1 antibody (1:2000)
provided by Dr. Isabell Greeve [1].
Cholesterol measurement
The amount of cholesterol in hMSC and hMSC-n was
determined by gas chromatography-mass spectrometry (GC-
MS) using stigmasterol as internal standard. hMSC were
harvested fromplates in PBSwith a rubber policeman, pelleted
by centrifugation and frozen in liquid nitrogen for storage at
−80°C. Cell pellets were homogenized in 20 mM Tris–HCl, pH7.6, with three short pulses of a polytron homogenizer
(Ultraturrax T8, IKA LABORTECHNIK, Germany). The protein
concentrationwas determined in the cell lysate by themethod
of Bradford [29] using bovine serum albumin as reference
standard. Aliquots corresponding to 5 μg of protein were used
for cholesterol determination. After the addition of stigmas-
terol (1000 ng), sterols were saponified in 1.5 ml of freshly
prepared 1 N NaOH in MeOH at 40°C for 60 min and
successively extracted with 2 ml of n-hexane. After evapora-
tion of the organic solvent, sterols were derivatized in 100 μl
of N,O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA) with
10% trimethyl-chlorosilane at 70°C for 30 min. Two micro-
liters of the BSTFA solutions was automatically injected for
analysis. A six-point calibration curve in the range 50–2000 ng
of cholesterol with 1000 ng of stigmasterol as internal
standard was used for cholesterol quantification. Each point
was obtained by adding the appropriate quantities of
cholesterol and internal standard and performing the same
procedure of the samples. Stock solutions (1 μg/μl) of
cholesterol and stigmasterol were prepared in ethanol. The
peak area ratios (PAR) were calculated using the signals at
458 m/z and 484 m/z for cholesterol and stigmasterol,
respectively. GC-MS analysis was conducted on a Hewlett-
Packard GC-MS system composed of a 5890 series II gas-
chromatograph equipped with a 5971A Mass Spectrometry
Detector and a 7673A automatic injector. The GC column was
a J&W DB1 (15 m × 0.25 mm × 0.25 μm), and the instrumental
conditions were as follows: injector temperature: 250°C;
temperature program of the GC column: 80 C × 1 min then
30°C/min to 240°C, then 5°C/min to 300°C, 300°C for 2 min.
Injections were performed in the splitless mode with a purge
off time of 1 min. SIM analyses were made acquiring the ions
458 m/z, 368 m/z, 353 m/z and 329 m/z for cholesterol and 484
m/z and 394 m/z for stigmasterol.
Statistical analysis
Datawere expressed asmean ± SE or SD. Statistical differences
were analyzed using one-way analysis of variance. Signifi-
cance was adjusted for multiple comparisons of means using
Bonferroni's approximation.Results
Characterization of hMSC
hMSC were successfully culture-expanded. A morphological-
ly homogeneous population of fibroblast-like cells with more
than 90% confluence was seen after 14 days, and after the
first passage, the cells grew exponentially, requiring weekly
passages: primary culture cells (14 days) were trypsinized
and replated, reaching a cellular expansion up to a 109–1010
factor in 5 months. The CFU-F assay was used as a surrogate
assay for hMSC: the estimated Colony Forming Unit Effi-
ciency of total nucleated cells was 50 ± 7 (mean ± SE)/106
cells.
Flow cytometry analysis was used to assess the purity of
hMSC cultures, which appeared uniformly positive for CD29
(β1 integrin), CD44 (receptor for hyaluronic acid), CD166
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CD90 (Thy-1), CD73 (ecto-5′-nucleotidase), HLA-ABC and
CD105 (type III TGFβ1–3 receptor or endoglin) (Fig. 1). HLA-DP
QRwas expressed in less than 2% of the population. There was
no detectable contamination of hemopoietic cells: in fact,
markers of the hemopoietic lineage, such as the lipopolysac-
charide receptor CD14, CD34 and the leucocyte common
antigen CD45, were not detectable (Fig. 1).
The expression of a panel of typical mesenchymal genes
was examined in order to confirm the mesenchymal deriva-
tion of the primary cultures. hMSC expressed detectable levels
of bone sialoprotein, osteocalcin, PPARγ, type I collagen and
alkaline phosphatase transcripts (Fig 2A).
Osteogenic, adipogenic and chondrogenic differentiation of
hMSC were readily inducible, further indicating that these
cells were of mesenchymal derivation (Fig. 2B).
Neuronal differentiation of hMSC
Starting from the first hours of neuronal induction of hMSC
(Fig. 3A) (see Materials and methods), the cells markedly
changed their morphology under light microscopy, showing a
neuronal-like phenotype (hMSC-n). Cytoplasm progressively
retracted towards the nucleus and some neurite-like process-Fig. 1 – Flow cytometric analysis of surface adhesion molecule
antibodies specific for molecules indicated in each flow cytomet
HLA-DP DQ DR; they are positive for CD105, CD166, CD90, CD73,es became apparent (Fig. 3B). 100% cell viability was docu-
mented after neuronal differentiation, thus excluding a toxic
effect of BME (not shown).
The cells were assessed for the expression of neuronal-
specific genes before and after neuronal induction by RT-PCR
analysis. Undifferentiated hMSC showed transcripts only for
nestin and GP4 (Fig 4A), two genes that are prevalently
expressed by neuronal progenitor cells, whereas hMSC-n
showed also transcripts for necdin and for the other
neuronal-specific markers NF-L and NOPP [15], as shown in
Fig. 4A. No amplified transcript for GFAP, a typical astrocyte
marker [15], was detectable. Further characterization of
differentiated neuronal cells was performed by immunocy-
tochemistry (Fig. 4B). Most of the hMSC exhibited strong
positive staining for nestin (Fig. 4Ba), whereas the positivity
was markedly reduced in hMSC-n. The expression of NF-M, a
neuronal-specific intermediate filament associated with
neuritogenesis, neural process outgrowth and appearance
of mature neuron morphology [30], was also tested. NF-M
was highly expressed by hMSC-n (Fig. 4Bb) but was totally
absent in hMSC. Positive staining for the established marker
of motor neurons ChAT [31] was strongly detected in hMSC-n
(Fig. 4Bc), whereas no signal was present in undifferentiated
hMSC. Moreover, the expression of NeuN, the neuronal-s on hMSC. Cultures of hMSC were labeled with monoclonal
ric histogram: they are negative for CD45, CD14, CD34 and
CD29, CD44 and HLA-ABC.
Fig. 2 – (A) Expression of typical mesenchymal genes in hMSC, as assessed by RT-PCR. Lanes 1 and 7, Molecular Weight
Marker XIV (Roche-Hoffmann, Basel, Switzerland); 2, bone sialoprotein; 3, osteocalcin; 4, PPARγ; 5, type I collagen; 6, alkaline
phosphatase. (B) Osteogenic (Alizarin Red S staining), adipogenic and chondrogenic differentiation (Toluidine Blue staining)
of hMSC after 3 weeks in differentiation media.
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did not exhibit any positive immunostaining for NeuN,
whereas hMSC-n showed an intense signal (Fig. 4Bd).
Electrophysiological studies
The cells were then assessed for the functional expression of
specific ionic channels. All the hMSC investigated in control
bath solution at a holding potential (HP) of −90 mV showed
outward currents. Most of them showed a relatively slowly
activating current (Fig. 5A) that occurred starting from −40 mVFig. 3 – hMSC (A) and hMSC-n (B) shownand slightly inactivated at positive potentials during 4.6-s-
long pulses. Cell capacitance was 40 ± 2 pF. Mean current
density was 19 ± 1.8 pA/pF at +50mV. Current–voltage relation
showed a change in steepness above +10 mV, suggesting the
presence of two different kinds of outward currents (Fig. 5C,
filled circles). To test whether the high voltage activated
current was due to MaxIK channel activation, the other K+
currents were blocked by setting the HP at −30 mV. In this
condition, the outward current arose from 0 mV, it was fast
activating and slightly inactivated at positive potentials (Fig.
5B). Mean current density was 15 ± 2.8 pA/pF at +50 mV.by phase contrast inverted microscopy.
Fig. 4 – (A) Expression of neuronal markers in hMSC and in hMSC-n, as assessed by RT-PCR. Lanes 1 and 8, nestin; 2 and 9,
necdin; 3 and 10, NF-L; 4 and 11, GFAP; 5 and 12, NOPP; 6 and 13, GP4; 7, Molecular Weight Marker XIV (Roche-Hoffmann). (B)
Immunocytochemistry showing positivity for nestin in hMSC (a) and for NF-M (b), ChAT (c) and NeuN (d) in hMSC-n.
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noise in the current recordings. I–V relation is showed in Fig 5C
(filled triangles). The observed characteristics of such a
current agree with MaxIK channel activation. Thus, outward
current recorded with control bath solution at −90 mV HP was
due to at least two kinds of K+ channels roughly corresponding
to Is and Ir (MaxIK) described by Heubach et al. [23]. The I–V
relation of Is was evaluated by subtracting the data obtained at
−30 mV from those at −90 mV HP (Fig. 5C, open circles). These
currents were blocked by TEA–Ca2+ bath solution, indicating
that they were K+ currents. Na+ and Ca2+ inward currents were
absent in all the cells investigated.
hMSC-n showed drastic differences of currents time
course. In control solution, inward transient currentspreceded outward currents (Fig. 5D). To evaluate the
involvement of functional Ca2+ channels, we used TEA–
Ca2+ bath solution (Fig. 6A). An inward transient current
was recorded from −50 mV with a peak at 80–100 ms.
From −30 mV, it is followed by a slower decay suggesting
the activation of HVA-type Ca2+ channels. Activation and
inactivation Boltzmann curve of these two currents agree
with T- and HVA-type of Ca2+ channels (Figs. 6C–E). This
was confirmed by using Cd2+ and nifedipine since none of
them affected T-type current (Fig. 6B). Instead, HVA-type
was blocked by Cd2+ but not completely by nifedipine.
Accordingly, HVA currents consist of the nifedipine-
sensitive L-type and also other Ca2+ currents such as N,
P, Q and R-types.
Fig. 5 – Ionic currents in hMSC and hMSC-n. Original current traces recorded in a typical hMSC in Control solution at a holding
potential of −90 mV (A) and −30 mV (B); voltage steps from −80 to 60 mV in 10-mV increments. (C) Related I–V curves (filled
circles, n = 9 cells) and −30 mV (filled triangles, n = 6 cells); open circles are data from the difference filled circles minus filled
squares data. Inward currents precede outward currents in hMSC-n (D).
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the contamination of K+ currents, we used 20 mM-TEA bath
solution to block K+ currents while the occurrence of T-type
Ca2+ current was avoided by inactivating channels at −60 mV
HP. In this experimental condition, we could record a fast
inward transient current, with a time to peak at 0.5 ms and
resolved in about 2 ms at −10 mV (Fig 6F). It activated from
−50 mV, and its current–voltage relation showed a maxi-
mum at −10 mV (Fig. 6G). The current density at the peak
was 18 pA/pF. The Boltzmann parameters values for
activation were Gmax = 12.7 pS, Va = −25 mV, ka = 7.4 and
Vrev = 61 mV and for inactivation were Vh = −70; kh = 7.4 mV
(Figs. 6G, H). The divergence between half values was 45 mV.
Since this current was not observed in TEA–Ca2+ bath
solution that was Na+-free and was blocked by TTX 1 μM,
we can reasonably assess that it is a Na+ current. Finally,
being the time constant of inactivation 0.5 ms at −10 mV, all
our data perfectly agree with the presence of Na+ channels
of neuronal type in these cells.
Expression and activity of seladin-1 in hMSC and in hMSC-n
The expression level of seladin-1 was evaluated by real-time
RT-PCR and by Western blot analysis. The amount of
seladin-1 transcript significantly decreased following neuro-
nal differentiation of hMSC (Fig. 7); similarly, the level of
seladin-1 protein also decreased in hMSC-n (Fig. 7). As an
additional clue that in our experimental conditions hMSC
were effectively differentiated into mature cells, we found a
lower expression level of the catalytic subunit of telomerase,
hTERT [33,34], in hMSC-n compared to undifferentiated cells(287 ± 21.8 vs. 8326 ± 732 ag/μg total RNA, mean ± SE,
p < 0.01).
In order to clarify whether the reduction of seladin-1
expressionmight be related to the oxidative status of the cells,
as shown by Wu et al. in immortalized fibroblasts, in which
H2O2 increased seladin-1 expression [35], hMSC were exposed
to H2O2 as well as to BME, which posseses anti-oxidant
activity. 20 and 100 μM H2O2 (a sublethal concentration for
hMSC) determined only a rapid and transient increase of
seladin-1 expression after 6 h followed by a marked decline
after 12 h. Exposure to 1 mM BME also determined an increase
of seladin-1 expression after 6 h followed by a decrease after
12 h (Fig. 8). It has to be mentioned that MSC assume some
neuronal characteristics already after a few hours of exposure
to BME [12]. As an additional demonstration that the reduced
level of expression of seladin-1 was associated to cell
differentiation of hMSC, a significant decrease of the amount
of transcript was observed when these cells were differenti-
ated into hMSC-n using retinoic acid (52.9 ± 9%, hMSC-n, vs.
100 ± 3.8%, hMSC, mean ± SE, p < 0.05), as described and
validated previously [15], instead of BME, or into osteoblasts
(25.5 ± 2%, mean ± SE, p < 0.05). In the latter case, ascorbic acid,
a known anti-oxidant agent, was among the factors used to
induce cell differentiation, according to the literature [18].
However, short-term exposure (12 h) to 50 μMascorbic acid did
not change the amount of seladin-1 mRNA in hMSC
(102.4 ± 3.5%, mean ± SE), compared to untreated cells.
As a further clue supporting the hypothesis that seladin-1
is a predominant product of stem cells, we also detected a high
amount of seladin-1 mRNA in the human adult hippocampus
and spinal cord, which have been shown to contain neural
Fig. 6 – Inward Ca2+ and Na+ currents in hMSC-n. (A) Typical current traces recorded in TEA–Ca2+ bath solution from an HP at
−90 mV; for clarity, only current traces from −60 to +20 mV are presented. The −30 mV traces clearly indicate the fast activating
and inactivating T-type Ca2+ current followed by a slower inactivating one (HVA). (B) HVA currents recorded at HP of −60 mV or
−90mVwith Nifedipine or Cd2+. (C) I–V relation determined at the current peak (n = 6); superimpose continuous line to the data
is the fit of the sum of two Boltzmann equations [Eq. (1)]; T and HVA lines are the related Boltzmann curves with Va = −45 mV,
ka = 4.4 and Vrev = 40 mV and Va = −20 mV, ka = 4.0 and Vrev = 40 mV. (D) Inactivation I–V relation evaluated at test potential of
−10 mV (n = 5): the best fit is obtained by a sum of two Boltzmann equations [Eq. (2)]; the related single Boltzmann fit is also
presented to put in evidence the T- and HVA-type Ca2+ current inactivation. (E) Normalized I–V relation for activation and
inactivation of T (dashed lines) and HVA-type (continuous line) Ca2+ currents from C and D; symbols are experimental data of
HVA Ca2+ current evaluated at test potential of −10mV from an HP −60mV. (F) Inward Na+ currents (INa) recorded in 20-TEA bath
solution at a holding potential of −60 mV. Representative current traces at voltage steps from −50 to +30 mV are shown;
numbers related to some current traces indicate the pulse potential. (G) I–V relationship for INa peak (n = 8). Smooth curve is a
Boltzmann curve from Eq. (1) with Va = −21 mV, ka = 6.7 and Erev = 51 mV. (H) Normalized inactivation curve in 20-TEA bath
solution determined by a test potential step to 0mV following 1 s conditioning steps from −90 to 30mV in 10-mV increments, HP
at −60mV; smooth curve superimposed on the data is a Boltzmann curve from Eq. (2) with Vh = −57mV, kh = 7.5. (The activation
curve fromG is depicted to show the overlappingwindowof potential whereNa+ channelsmay simultaneously activate and are
partially available to activate).
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seladin-1 mRNA in these regions was rather close to the
amount of transcript detected in the adrenal cortex, one of the
tissues in which the highest levels of transcription had been
detected [1]. In the thyroid gland, one of the organs in whichlow levels of seladin-1 mRNA had been observed [1], a
markedly lower amount of transcript was detected (Table 1).
Finally, in order to test whether the reduced expression of
seladin-1 in hMSC-n was paralleled by a decrease in choles-
terol content, the amount of total cholesterol was determined
Fig. 7 – Amount of seladin-1mRNA (top) and protein (bottom)
in hMSC and in hMSC-n, determined by real-time RT-PCR
and by Western blot analysis, respectively. C+, positive
control, i.e. adrenal cortex [24].
Table 1 – Amount of seladin-1 mRNA in different human
adult tissues (mean ± SE)
Tissues Seladin-1 mRNA
Hippocampus 5.16 ± 0.31 pg/μg total RNA
Spinal cord 6.97 ± 0.86 pg/μg total RNA
Adrenal cortex 8.82 ± 1.41 pg/μg total RNA
Thyroid 30.5 ± 3.34 fg/μg total RNA
2601E X P E R I M E N T A L C E L L R E S E A R C H 3 1 2 ( 2 0 0 6 ) 2 5 9 2 – 2 6 0 4by GC-MS in both hMSC and hMSC-n. Noticeably, a significant
lower level of total cholesterol was measured in hMSC-n
(155.1 ± 4.9 ng vs. 179.4 ± 1.3 ng, mean ± SD, p < 0.01).Discussion
The discovery of the seladin-1 gene and the finding that its
expression is down-regulated in the brain areas affected in
AD, the most prevalent form of late-life mental failure in
humans [1], opened a new window for understanding the
molecular events associated with neurodegeneration.
The aim of our study was to investigate on a possible
explanation to the impaired seladin-1 expression in ADFig. 8 – Effect of BME and H2O2 on seladin-1 mRNA in hMSC.vulnerable areas. The fact that some of these regions, namely
the hippocampus and the subventricular zone, correspond to
the areas which host stem cells with neurogenic potential and
migratory activity in the adult brain [8], led us to hypothesize
that seladin-1 might be a predominant product of multipotent
cells. Therefore, we compared the amount of expression of the
seladin-1 gene in stem cells and in neuronal-like cells derived
from them. Human MSC served as the multipotent cell model
because they are much more easily obtainable than neuronal
stem cells, and we rationalized that they might represent an
acceptable alternative to the use of neuronal stem cells in our
experimental setting. In fact, in vitro and in vivo neuronal
differentiation of MSC into neurons has been demonstrated
[12–15]. In addition, transplanted bonemarrow cells have been
localized in mouse [36] and human brain [37,38], suggesting a
possible differentiation into neuronal cells. Recently, MSC
have been injected intravenously, with encouraging results,
into animals affected by experimental demyelination, ische-
mic stroke, amyotrophic lateral sclerosis and spinal cord
injury [39] and also in humans affected by metachromatic
leukodystrophy and Hurler syndrome, which present with
severe neurological defects [40]. The functional/structural
parallelism between neuronal stem cells and MSC has been
underlined by the proposal to use terms like “neuropoiesis” to
indicate the persistence of neurogenesis in the adult brain and
“brain marrow” to describe the brain regions that contain cells
supporting neurogenesis [41,42].
A fundamental point when working with stem cells is a
thorough morphological and molecular characterization of
these cells. In addition, each differentiation protocol has to be
validated in order to exclude the presence of artifacts.
Therefore, a substantial part of our work was dedicated to
these aspects. hMSC were characterized by the analysis of the
expression of representative genes and by the ability to
differentiate into classical mesenchymal derivatives (i.e. fat,
bone, cartilage). Neuronal differentiation was induced accord-
ing to Woodbury et al. [12] and was validated by the
demonstration of the expression of neuronal-specific mar-
kers, such as NF-L, NF-M, NOPP, ChAT, NeuN and necdin. In
addition, thorough electrophysiological evaluation demon-
strated that hMSC-n show Na+ (INa) and Ca2+ (ICa) currents.
These currents were consistently observed in all the cells and
showed a larger current density compared to those reported
for hMSC. Noticeably, the current time course and voltage
dependence were different from those observed in hMSC [43],
strongly supporting the idea that new types of functional ionic
channels are expressed in hMSC-n. These channels were very
likely of neuronal type, as suggested by additional experi-
ments indicating that T- and HVA-Ca2+ channels of neuronal
phenotype were expressed. Notably, these Ca2+ currents are
those reported in neurons [44,45], whereas cardiac and
2602 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 2 ( 2 0 0 6 ) 2 5 9 2 – 2 6 0 4skeletal muscle express T and L-type channels with different
properties [46,47]. With regard to the Na+ current, Boltzmann
parameters were also consistent with those found in differ-
entiated neurons [48,49] and differed from those observed in
cardiac and skeletal muscle cells [50].
The amount of both seladin-1 mRNA and protein markedly
decreased in hMSC-n compared to hMSC. Accordingly, the
expression level of the catalytic subunit of telomerase hTERT
dramatically decreased after cell differentiation. This finding
is in agreement with the fact that telomerase is highly
expressed in germ and stem cells, including MSC, and its
expression has been related to the differentiating ability [33].
Conversely, low levels of expression are detected in quiescent
or terminally differentiated cells [34]. In agreement with the
reduced amount of expression of seladin-1, the content of
total cholesterol was found to be significantly decreased in
hMSC-n.
Because a previous study reported that sublethal doses of
H2O2 were able to increase seladin-1 expression in immortal-
ized fibroblasts (yet the maximum effect was observed after
12 h of treatment and was markedly decreased after 24 h) [35],
we wondered whether the oxidative status of hMSC might
influence seladin-1 expression. We found that H2O2 deter-
mined only a rapid (after 6 h) and transient increase of seladin-
1 transcript followed by a marked decrease after 12 h. Similar
results were obtained upon exposure to BME, which was used
in our experimental design to induce neuronal differentiation
and which possesses anti-oxidant activity. The fact that after
a few hours of exposure to BME MSC already assume some
neuronal characteristics [12] supports the hypothesis that the
decrease of seladin-1 expression is associated to cell differen-
tiation. Furthermore, we have shown that also upon induction
of neuronal differentiation using another differentiating
factor (i.e. retinoic acid), instead of BME, the amount of
seladin-1 transcript was significantly reduced. As a further
clue that the decreased expression of seladin-1 is linked to the
differentiation process, we obtained a significant reduction of
the amount of mRNA also following differentiation of hMSC
into osteoblasts.
The results here reported represent the first demonstration
that the seladin-1 gene is a predominant product of stem cells.
On the basis of these observations, it could be suggested that
the defective seladin-1 expression detected in AD vulnerable
brain regionsmay be linked to an impaired neuronal stem cell
compartment that could be a potential risk factor to develop
this disease. With regard to this point, it is worth mentioning
that, according to the findings of Greeve et al. [1], we detected
high levels of seladin-1 transcript in the adult hippocampus, a
well-known neurogenic brain region [8], and which is one of
the areas affected in AD. Similarly, a high amount of seladin-1
mRNA was found in the spinal cord, in which stem cells with
neurogenic properties have been recently described [9,10].
Alternatively, our findings might indicate a modification of
the neurogenic properties of the adult brain as a consequence
of neuronal damage and therefore of AD itself. In agreement
with the latter hypothesis, decreased proliferation of neuronal
precursors has been observed in animal models of AD, and it
has been linked to β-amyloid toxicity [51]. In any case, the
decrease of seladin-1 expression might be viewed as a marker
of neuronal damage in AD [1].Finally, although the data presented in this study should be
further supported by additional experimental strategies
involving different stem cell models, in view of our results, it
is tempting to speculate that reinforced seladin-1 expression
might be an additional point to be raised in favor of a stem-
cell-based therapy in AD, once several critical issues (i.e. the
ideal stem cells source for transplantation, the route of
administration, the achievement of an appropriate and long-
lasting integration of transplanted stem cells into the host
tissue) will be solved [39].Acknowledgments
This study was partially supported by grants from Regione
Toscana (TRESOR project, principal investigator Prof. Mario
Serio) and from Ente Cassa di Risparmio di Firenze.R E F E R E N C E S
[1] I. Greeve, I. Hermans-Borgmeyer, C. Brellinger, D. Kasper,
T. Gomez-Isla, C. Behl, B. Levkau, R.M. Nitsch, The human
DIMINUTO/DWARF1 homolog seladin-1 confers resistance
to Alzheimer's disease-associated neurodegeneration and
oxidative stress, J. Neurosci. 20 (2000) 7345–7352.
[2] S. Benvenuti, P. Luciani, G.B. Vannelli, S. Gelmini,
E. Franceschi, M. Serio, A. Peri, Estrogen and SERMs exert
neuroprotective effects and stimulate the expression of
seladin-1, a recently discovered anti-apoptotic gene, in
human neuroblast long-term cell cultures, J. Clin. Endocrinol.
Metab. 90 (2005) 1775–1782.
[3] H.R. Waterham, J. Koster, G.J. Romeijn, R.C.M. Hennekam,
P. Vreken, H.C. Andersson, D.R. FitzPatrick, R.I. Kelley, R.J.A.
Wanders, Mutations in the 3beta-hydroxysterol
Delta24-reductase gene cause desmosterolosis, an autosomal
recessive disorder of cholesterol biosynthesis, Am. J. Hum.
Genet. 69 (2001) 685–694.
[4] N. Arispe, M. Doh, Plasmamembrane cholesterol controls the
cytotoxicity of Alzheimer's disease AbetaP (1–40) and (1–42)
peptides, FASEB J. 16 (2002) 1526–1536.
[5] T.C. McMorris, Recent developments in the field of plant
steroid hormones, Lipids 32 (1997) 1303–1308.
[6] G.J. Bishop, T. Nomura, T. Yokota, K. Harrison, T. Noguchi,
S. Fujioka, S. Takatsuto, J.D. Jones, Y. Kamiya, The tomato
DWARF enzyme catalyses C-6 oxidation in brassinosteroid
biosynthesis, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
1761–1766.
[7] D.J. Selkoe, Alzheimer's disease: genes, proteins, and therapy,
Physiol. Rev. 81 (2001) 741–776.
[8] D.C. Lie, H. Song, S.A. Colamarino, G.L. Ming, F.H. Gage,
Neurogenesis in the adult brain: new strategies for central
nervous system diseases, Annu. Rev. Pharmacol. Toxicol. 44
(2004) 399–421.
[9] Y. Ke, L. Chi, R. Xu, C. Luo, D. Gozal, R. Liu, Early
response of endogenous adult neural progenitor cells to
acute spinal cord injury in mice, Stem Cells 24 (2006)
34–43.
[10] A.I. Danilov, R. Covacu, M.C. Moe, I.A. Langmoen, C.B.
Johansson, T. Olsson, L. Brundin, Neurogenesis in the adult
spinal cord in an experimental model of multiple sclerosis,
Eur. J. Neurosci. 23 (2006) 394–400.
[11] S. Temple, The development of neural stem cells, Nature 414
(2001) 112–117.
[12] D. Woodbury, E.J. Schwarz, D.J. Prockop, I.B. Black, Adult rat
2603E X P E R I M E N T A L C E L L R E S E A R C H 3 1 2 ( 2 0 0 6 ) 2 5 9 2 – 2 6 0 4and human bone marrow stromal cells differentiate into
neurons, J. Neurosci. Res. 61 (2000) 364–370.
[13] D. Woodbury, K. Reynolds, I.B. Black, Adult bone marrow
stromal stem cells express germline, ectodermal,
endodermal and mesodermal genes prior to neurogenesis,
J. Neurosci. Res. 69 (2002) 908–917.
[14] Y. Jiang, B.N. Jahagirdar, R.L. Reinhardt, R.E. Schwartz,
C.D. Keene, X.R. Ortiz-Gonzalez, M. Reyes, T. Lenvik, T.
Lund, M. Blackstad, J. Du, S. Aldrich, A. Lisberg, W.C.
Low, D.A. Largaespada, C.M. Verfaillie, Pluripotency of
mesenchymal stem cells derived from adult bone
marrow, Nature 418 (2002) 41–49.
[15] J.R. Sanchez-Ramos, Neural cells derived from adult bone
marrow and umbilical cord blood, J. Neurosci. Res. 69 (2002)
880–893.
[16] H. Castro-Malaspina, Characterization of human bone
marrow fibroblast colony-forming cells (CFU-F) and their
progeny, Blood 56 (1980) 289–301.
[17] A.J. Friedenstein, Precursor cells of mechanocytes, Int. Rev.
Cytol. 47 (1976) 327–359.
[18] M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal,
R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti,
S. Craig, D.R. Marshak, Multilineage potential of adult
human mesenchymal stem cells, Science 284 (1999)
143–147.
[19] H.R. Haase, S. Ivanovski, M.J. Waters, P.M. Bartold, Growth
hormone regulates osteogenic marker mRNA expression in
human periodontal fibroblasts and alveolar bone-derived
cells, J. Periodontal. Res. 38 (2003) 366–374.
[20] N. Ohara, Y. Hayashi, S. Yamada, S.K. Kim, T. Matsunaga,
K. Yanagiguchi, T. Ikeda, Early gene expression analyzed by
cDNA microarray and RT-PCR in osteoblasts cultured with
watersoluble and low-molecular chitooligosaccharide,
Biomaterials 25 (2004) 1749–1754.
[21] T. Kubota, K. Koshizuka, E.A. Williamson, H. Asou, J.W. Said,
S. Holden, I. Miyoshi, H.P. Koeffler, Ligand for peroxisome
proliferator-activated receptor gamma (troglitazone) has
potent antitumor effects against human prostate cancer both
in vitro and in vivo, Cancer Res. 58 (1998) 3344–3352.
[22] J.R. Sanchez-Ramos, S. Song, S.G. Kamath, T. Zigova, A.
Willing, F. Cardozo-Pelaez, T. Stedeford, M. Chopp, P.R.
Sanberg, Expression of neural markers in human umbilical
cord blood, Exp. Neurol. 171 (2001) 109–115.
[23] J.F. Heubach, E.M. Graf, J. Leutheuser, M. Bock, B. Balana,
I. Zahanich, T. Christ, S. Boxberger, E. Wettwer, U. Ravens,
Electrophysiological properties of humanmesenchymal stem
cells, J. Physiol. 554 (2004) 659–672.
[24] F. Francini, C. Bencini, C. Piperio, R. Squecco, Separation of
charge movement components in mammalian skeletal
muscle fibres, J. Physiol. 537 (2001) 45–56.
[25] L. Formigli, E. Meacci, C. Sassoli, F. Chellini, R. Giannini,
F. Quercioli, B. Tiribilli, R. Squecco, P. Bruni, F. Francini,
S. Zecchi-Orlandini, Sphingosine 1-phosphate induces
cytoskeletal reorganization in C2C12myoblasts: physiological
relevance for stress fibres in the modulation of ion current
through stretch-activated channels, J. Cell Sci. 118 (2005)
1161–1171.
[26] T. Yajima, A. Yagihashi, H. Kameshima, D. Furuya,
D. Kobayashi, K. Hirata, N. Watanabe, Establishment of
quantitative reverse transcription-polymerase chain reaction
assays for human telomerase-associated genes, Clin. Chim.
Acta 290 (2000) 117–127.
[27] P. Luciani, P. Ferruzzi, G. Arnaldi, C. Crescioli, S. Benvenuti,
A. Valeri, I. Greeve, M. Serio, M. Mannelli, A. Peri, Expression
of the novel adrenocorticotropin-responsive gene selective
Alzheimer's disease indicator-1 in the normal adrenal cortex
and in adrenocortical adenomas and carcinomas, J. Clin.
Endocrinol. Metab. 89 (2004) 1332–1339.
[28] S.A Bustin, Quantification of mRNA using real-time reversetranscription PCR (RT-PCR): trends and problems, J. Mol.
Endocrinol. 29 (2002) 23–39.
[29] M.M. Bradford, A rapid sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of
protein-dye binding, Anal. Biochem. 72 (1976) 248–254.
[30] M.J. Carden, J.Q. Trojanowski, W.W. Schlaepfter, V.M. Lee,
Two-stage expression of neurofilament polypeptides during
rat neurogenesis with early establishment of adult
phosphorylation patterns, Neuroscience 7 (1987) 3489–3504.
[31] P. Tirassa, V. Triaca, T. Amendola, M. Fiore, L. Aloe, EGF and
NGF injected into the brain of old mice enhance BDNF
synthesis and increase the number of Ki67 and
CHAT-positive cells in the subventricular zone, J. Neurosci.
Res. 72 (2003) 557–564.
[32] H.B. Sarnat, D. Nochlin, D.E. Born, Neuronal nuclear antigen
(NeuN): amarker of neuronalmaturation in early human fetal
nervous system, Brain Res. 20 (1998) 88–94.
[33] L. Liu, C.M. DiGirolamo, P.A. Navarro, M.A. Blasco, D.L. Keefe,
Telomerase deficiency impairs differentiation of
mesenchymal stem cells, Exp. Cell Res. 294 (2004) 1–8.
[34] J. Feng, W.D. Funk, S.-S. Wang, S.L. Weinrich, A.A. Avilion,
C.P. Chiu, R.R. Adams, E. Chang, R.C. Allsopp, J. Yu, The RNA
component of human telomerase, Science 269 (1995)
1236–1241.
[35] C. Wu, I. Miloslavskaya, S. Demontis, R. Maestro,
K. Galaktionov, Regulation of cellular response to oncogenic
and oxidative stress by Seladin-1, Nature 432 (2004) 640–645.
[36] E. Mezey, K.J. Chandross, G. Harta, Turning blood into brain:
cells bearing neuronal antigens generated in vivo from bone
marrow, Science 290 (2000) 1779–1782.
[37] E. Mezey, S. Key, G. Vogelsang, I. Szalayova, G.D. Lange,
B. Crain, Transplanted bone marrow generates new
neurons in human brain, Proc. Natl. Acad. Sci. 100 (2003)
1364–1369.
[38] J.M. Weimann, C.A. Charlton, T.R. Brazelton, R.C. Hackman,
H.M. Blau, Contribution of transplanted bone marrow cells to
Purkinje neurons in human adult brains, Proc. Natl. Acad. Sci.
100 (2003) 2088–2093.
[39] S. Pluchino, L. Zanotti, M. Deleidi, G. Martino, Neural stem
cells and their use as therapeutic tool in neurological
disorders, Brain Res. Rev. 48 (2005) 211–219.
[40] O.N. Koc, J. Day, M. Nieder, S.L. Gerson, H.M. Lazarus,
W. Krivit, Allogeneic mesenchymal stem cell infusion for
treatment of metachromatic leukodystrophy (MLD) and
Hurler syndrome (MPS-ICH), Bone Marrow Transplant. 30
(2002) 215–222.
[41] D.A. Steindler, T. Kadrie, H. Fillmore, L.B. Thomas, The
subependymal zone: “brain marrow”, Prog. Brain Res. 108
(1996) 349–363.
[42] B. Scheffer, M. Horn, I. Blumcke, E.D. Laywell, D. Coomes, V.G.
Kukekov, D.A. Steindler, Marrow-mindedness: a perspective
on neuropoiesis, Trends Neurosci. 22 (1999) 348–357.
[43] G. Li, S. Haiying, X. Deng, C.P. Lau, Characterization of ionic
currents in human mesenchymal stem cells from bone
marrow, Stem Cells 23 (2005) 371–382.
[44] S.M. Todorovic, V. Jevtovic-Todorovic, S. Mennerick,
E. Perez-Reyes, C.F. Zorumski, Ca(v)3.2 channel is a molecular
substrate for inhibition of T-type calcium currents in rat
sensory neurons by nitrous oxide, Mol. Pharmacol. 60 (2001)
603–610.
[45] N. Joux, V. Chevaleyre, G. Alonso, L. Boissin-Agasse, F.C.
Moos, M.G. Desarmenien, N. Hussy, High voltage-activated
Ca2+ currents in rat supraoptic neurones: biophysical
properties and expression of the various channel alpha1
subunits, J. Neuroendocrinol. 13 (2001) 638–649.
[46] K.G. Beam, C.M. Knudson, Calcium currents in embryonic and
neonatal mammalian skeletal muscle, J. Gen. Physiol. 91
(1988) 781–798.
[47] C. Bencini, R. Squecco, C. Piperio, L. Formigli, E. Meacci,
2604 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 2 ( 2 0 0 6 ) 2 5 9 2 – 2 6 0 4D. Nosi, B. Tiribilli, M. Vassalli, F. Quercioli, P. Bruni, S. Zecchi
Orlandini, F. Francini, Effects of sphingosine 1-phosphate on
excitation–contraction coupling in mammalian skeletal
muscle, J. Muscle Res. Cell. Motil. 24 (2003) 539–554.
[48] N. Yoshimura, W.C. De Groat, Characterization of
voltage-sensitive Na+ and K+ currents recorded from acutely
dissociated pelvic ganglion neurons of the adult rat,
J. Neurophysiol. 76 (1996) 2508–2521.
[49] M. Albrieux, J.C. Platel, A. Dupuis, M. Villaz, W.J. Moody, Early
expression of sodium channel transcripts and sodiumcurrent by Cajal-Retzius cells in the preplate of the embryonic
mouse neocortex, J. Neurosci. 24 (2004) 1719–1725.
[50] T. Zimmer, C. Bollensdorff, V. Haufe, E. Birch-Hirschfeld, K.
Benndorf, Mouse heart Na+ channels: primary structure and
function of two isoforms and alternatively spliced variants,
Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) 1007–1017.
[51] N.J. Haughey, A. Nath, S.L. Chan, A.C. Borchard, M.S. Rao, M.P.
Mattson, Disruption of neurogenesis by β-peptide, and
perturbed neural progenitor cell homeostasis, in models of
Alzheimer's disease, J. Neurochem. 83 (2002) 1509–1524.
